1-6 of 6
Tao Meng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation

Hangtian Yue, Hui Xu, Lanping Ma, Xiyuan Li, Biyu Yang, Xiyuan Wang, Qingzhong Zeng, Han Li, Deqiang Zhang, Meiyu Geng, Tao Meng, Zuoquan Xie
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (11): 1639–1651.
https://doi.org/10.1158/1535-7163.MCT-24-0078
Published: 04 November 2024
View article titled, A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation
Open the PDF for A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation in another window
Includes: Supplementary data
Journal Articles

MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors

Chao Kong, Junyi Pu, Qianqian Zhao, Weining Weng, Linjie Ma, Yu Qian, Wenhao Hu, Xun Meng, Tao Meng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (10): 1128–1143.
https://doi.org/10.1158/1535-7163.MCT-23-0164
Published: 02 October 2023
View article titled, MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors
Open the PDF for MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors in another window
Includes: Supplementary data
Journal Articles

AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors

Weining Weng, Tao Meng, Junyi Pu, Linjie Ma, Yi Shen, Zhaohui Wang, Rong Pan, Mingqiao Wang, Caiwei Chen, Lijun Wang, Jianjian Zhang, Biao Zhou, Siyuan Shao, Yu Qian, Shuhui Liu, Wenhao Hu, Xun Meng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (9): 1013–1027.
https://doi.org/10.1158/1535-7163.MCT-23-0198
Published: 05 September 2023
View article titled, AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors
Open the PDF for AMT-562, a Novel HER3-targeting Antibody–Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors in another window
Includes: Supplementary data
Journal Articles

Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers

Wei Zhou, Peng Fang, Dongan Yu, Hongyuan Ren, Meng You, Long Yin, Fei Mei, Huikai Zhu, Zhenzhen Wang, Hui Xu, Yuxia Cao, Xiaowei Sun, Xiaohong Xu, Jianjun Bi, Jin Wang, Lanping Ma, Xin Wang, Lin Chen, Yongliang Zhang, Xiaowei Cen, Xi Zhu, Liguang Lou, Datao Liu, Xiaoding Tan, Jinliang Yang, Tao Meng, Jingkang Shen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (8): 913–925.
https://doi.org/10.1158/1535-7163.MCT-22-0743
Published: 01 August 2023
View article titled, Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Open the PDF for Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers in another window
Includes: Supplementary data
Journal Articles

Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Rui Jin, Liang Liu, Yun Xing, Tao Meng, Lanping Ma, Jinpeng Pei, Ying Cong, Xuesai Zhang, Zhiqiang Ren, Xin Wang, Jingkang Shen, Ker Yu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (11): 2340–2352.
https://doi.org/10.1158/1535-7163.MCT-20-0076
Published: 03 November 2020
View article titled, Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function
Open the PDF for Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function in another window
Includes: Supplementary data
Journal Articles

MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189

Wei Wang, Ying-Qing Wang, Tao Meng, Jun-Mei Yi, Xia-Juan Huan, Lan-Ping Ma, Lin-Jiang Tong, Yi Chen, Jian Ding, Jing-Kang Shen, Ze-Hong Miao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (6): 1480–1491.
https://doi.org/10.1158/1535-7163.MCT-13-0629
Published: 04 June 2014
View article titled, MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189
Open the PDF for MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189 in another window
Includes: Supplementary data